135 related articles for article (PubMed ID: 38041219)
21. Conjunctival Melanoma Targeted Therapy: MAPK and PI3K/mTOR Pathways Inhibition.
El Zaoui I; Bucher M; Rimoldi D; Nicolas M; Kaya G; Pescini Gobert R; Bedoni N; Schalenbourg A; Sakina E; Zografos L; Leyvraz S; Riggi N; Rivolta C; Moulin AP
Invest Ophthalmol Vis Sci; 2019 Jun; 60(7):2764-2772. PubMed ID: 31247083
[TBL] [Abstract][Full Text] [Related]
22. Horizontal Combination of MEK and PI3K/mTOR Inhibition in BRAF Mutant Tumor Cells with or without Concomitant PI3K Pathway Mutations.
Rittler D; Molnár E; Baranyi M; Garay T; Hegedűs L; Aigner C; Tóvári J; Tímár J; Hegedűs B
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081092
[TBL] [Abstract][Full Text] [Related]
23. Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma.
Villanueva J; Infante JR; Krepler C; Reyes-Uribe P; Samanta M; Chen HY; Li B; Swoboda RK; Wilson M; Vultur A; Fukunaba-Kalabis M; Wubbenhorst B; Chen TY; Liu Q; Sproesser K; DeMarini DJ; Gilmer TM; Martin AM; Marmorstein R; Schultz DC; Speicher DW; Karakousis GC; Xu W; Amaravadi RK; Xu X; Schuchter LM; Herlyn M; Nathanson KL
Cell Rep; 2013 Sep; 4(6):1090-9. PubMed ID: 24055054
[TBL] [Abstract][Full Text] [Related]
24. Insulin induces drug resistance in melanoma through activation of the PI3K/Akt pathway.
Chi M; Ye Y; Zhang XD; Chen J
Drug Des Devel Ther; 2014; 8():255-62. PubMed ID: 24600206
[TBL] [Abstract][Full Text] [Related]
25. Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma.
Lassen A; Atefi M; Robert L; Wong DJ; Cerniglia M; Comin-Anduix B; Ribas A
Mol Cancer; 2014 Apr; 13():83. PubMed ID: 24735930
[TBL] [Abstract][Full Text] [Related]
26. Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma.
Fattore L; Malpicci D; Marra E; Belleudi F; Noto A; De Vitis C; Pisanu ME; Coluccia P; Camerlingo R; Roscilli G; Ribas A; Di Napoli A; Torrisi MR; Aurisicchio L; Ascierto PA; Mancini R; Ciliberto G
Oncotarget; 2015 Sep; 6(28):24823-41. PubMed ID: 26208478
[TBL] [Abstract][Full Text] [Related]
27. Targeting p63 Upregulation Abrogates Resistance to MAPK Inhibitors in Melanoma.
Patel A; Garcia LF; Mannella V; Gammon L; Borg TM; Maffucci T; Scatolini M; Chiorino G; Vergani E; Rodolfo M; Maurichi A; Posch C; Matin RN; Harwood CA; Bergamaschi D
Cancer Res; 2020 Jun; 80(12):2676-2688. PubMed ID: 32291316
[TBL] [Abstract][Full Text] [Related]
28. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
[TBL] [Abstract][Full Text] [Related]
29. HI-511 overcomes melanoma drug resistance
Chang X; Zhang T; Wang Q; Rathore MG; Reddy K; Chen H; Shin SH; Ma WY; Bode AM; Dong Z
Theranostics; 2020; 10(21):9721-9740. PubMed ID: 32863956
[No Abstract] [Full Text] [Related]
30. Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance.
Raaijmakers MI; Widmer DS; Narechania A; Eichhoff O; Freiberger SN; Wenzina J; Cheng PF; Mihic-Probst D; Desalle R; Dummer R; Levesque MP
Oncotarget; 2016 Nov; 7(47):77163-77174. PubMed ID: 27791198
[TBL] [Abstract][Full Text] [Related]
31. In Vitro Experiments on the Effects of GP-2250 on BRAF-Mutated Melanoma Cell Lines and Benign Melanocytes.
Gambichler T; Harnischfeger F; Skrygan M; Majchrzak-Stiller B; Buchholz M; Müller T; Braumann C
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895015
[TBL] [Abstract][Full Text] [Related]
32. Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma.
Ma XH; Piao SF; Dey S; McAfee Q; Karakousis G; Villanueva J; Hart LS; Levi S; Hu J; Zhang G; Lazova R; Klump V; Pawelek JM; Xu X; Xu W; Schuchter LM; Davies MA; Herlyn M; Winkler J; Koumenis C; Amaravadi RK
J Clin Invest; 2014 Mar; 124(3):1406-17. PubMed ID: 24569374
[TBL] [Abstract][Full Text] [Related]
33. A Bifunctional MAPK/PI3K Antagonist for Inhibition of Tumor Growth and Metastasis.
Galbán S; Apfelbaum AA; Espinoza C; Heist K; Haley H; Bedi K; Ljungman M; Galbán CJ; Luker GD; Dort MV; Ross BD
Mol Cancer Ther; 2017 Nov; 16(11):2340-2350. PubMed ID: 28775144
[TBL] [Abstract][Full Text] [Related]
34. Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?
Kelley MC
Crit Rev Oncog; 2016; 21(1-2):83-91. PubMed ID: 27481005
[TBL] [Abstract][Full Text] [Related]
35. BRAFV600E cooperates with PI3K signaling, independent of AKT, to regulate melanoma cell proliferation.
Silva JM; Bulman C; McMahon M
Mol Cancer Res; 2014 Mar; 12(3):447-63. PubMed ID: 24425783
[TBL] [Abstract][Full Text] [Related]
36. p53 Family in Resistance to Targeted Therapy of Melanoma.
Vlašić I; Horvat A; Tadijan A; Slade N
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613518
[TBL] [Abstract][Full Text] [Related]
37. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.
Atefi M; von Euw E; Attar N; Ng C; Chu C; Guo D; Nazarian R; Chmielowski B; Glaspy JA; Comin-Anduix B; Mischel PS; Lo RS; Ribas A
PLoS One; 2011; 6(12):e28973. PubMed ID: 22194965
[TBL] [Abstract][Full Text] [Related]
38. PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.
Niessner H; Schmitz J; Tabatabai G; Schmid AM; Calaminus C; Sinnberg T; Weide B; Eigentler TK; Garbe C; Schittek B; Quintanilla-Fend L; Bender B; Mai M; Praetorius C; Beissert S; Schackert G; Muders MH; Meinhardt M; Baretton GB; Dummer R; Flaherty K; Pichler BJ; Kulms D; Westphal D; Meier F
Clin Cancer Res; 2016 Dec; 22(23):5818-5828. PubMed ID: 27307593
[TBL] [Abstract][Full Text] [Related]
39. Repurposing the serotonin agonist Tegaserod as an anticancer agent in melanoma: molecular mechanisms and clinical implications.
Liu W; Stachura P; Xu HC; Umesh Ganesh N; Cox F; Wang R; Lang KS; Gopalakrishnan J; Häussinger D; Homey B; Lang PA; Pandyra AA
J Exp Clin Cancer Res; 2020 Feb; 39(1):38. PubMed ID: 32085796
[TBL] [Abstract][Full Text] [Related]
40. Identification of NRAS isoform 2 overexpression as a mechanism facilitating BRAF inhibitor resistance in malignant melanoma.
Duggan MC; Stiff AR; Bainazar M; Regan K; Olaverria Salavaggione GN; Maharry S; Blachly JS; Krischak M; Walker CJ; Latchana N; Tridandapani S; de la Chapelle A; Eisfeld AK; Carson WE
Proc Natl Acad Sci U S A; 2017 Sep; 114(36):9629-9634. PubMed ID: 28827320
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
